BioCentury
ARTICLE | Deals

Janssen takes another shot at off-the-shelf CAR Ts with Fate deal

April 3, 2020 7:36 PM UTC
Updated on Apr 3, 2020 at 11:13 PM UTC

Janssen is adding an off-the-shelf CAR-T and CAR-NK technology to build out its cancer cell therapy pipeline through a deal with Fate Therapeutics, marking at least the second time the company has partnered for allogeneic CAR T cells.

Fate Therapeutics Inc. gained $1.87 to $22.94 on the news of its first research and licensing deal in 18 months. ...